Longboard Pharmaceuticals, Inc. (LBPH) Bundle
Understanding Longboard Pharmaceuticals, Inc. (LBPH) Revenue Streams
Understanding Longboard Pharmaceuticals, Inc.’s Revenue Streams
As of September 30, 2024, Longboard Pharmaceuticals, Inc. has not generated any revenue from product sales. The company primarily funds its operations through equity offerings.
Breakdown of Primary Revenue Sources
Since inception, the company has not established significant revenue streams from products or services. It relies entirely on capital raised through public and private offerings to finance its operations.
Year-over-Year Revenue Growth Rate
Longboard Pharmaceuticals has not reported any revenue, thus year-over-year growth rates based on revenue are not applicable. The company continues to incur net losses, which were reported as follows:
- Net loss for the three months ended September 30, 2024: $24.5 million
- Net loss for the three months ended September 30, 2023: $12.9 million
- Net loss for the nine months ended September 30, 2024: $61.3 million
- Net loss for the nine months ended September 30, 2023: $39.4 million
Contribution of Different Business Segments to Overall Revenue
As there are no revenue-generating business segments, the contribution to overall revenue is $0. All financial activity is related to funding through equity.
Analysis of Any Significant Changes in Revenue Streams
There have been no changes in revenue streams as the company has not commenced product sales. The focus remains on raising funds for research and development activities.
Financial Data Summary
| Period | Net Loss (in millions) | Accumulated Deficit (in millions) | Cash, Cash Equivalents, and Short-term Investments (in millions) |
|---|---|---|---|
| Q3 2024 | $24.5 | $201.9 | $288.4 |
| Q3 2023 | $12.9 | $140.6 | $48.5 |
As of September 30, 2024, the company has incurred substantial net losses since inception, indicating a reliance on external financing rather than revenue generation from product sales.
A Deep Dive into Longboard Pharmaceuticals, Inc. (LBPH) Profitability
A Deep Dive into Longboard Pharmaceuticals, Inc.'s Profitability
Gross Profit, Operating Profit, and Net Profit Margins
For the three months ended September 30, 2024, the company reported a net loss of $24.5 million, while for the nine months ended September 30, 2024, the net loss was $61.3 million. The operating expenses for the three months were $28.1 million, which includes $21.5 million in research and development and $6.7 million in general and administrative expenses.
| Period | Net Loss (in millions) | Operating Expenses (in millions) | R&D Expenses (in millions) | G&A Expenses (in millions) |
|---|---|---|---|---|
| Q3 2024 | $24.5 | $28.1 | $21.5 | $6.7 |
| 9M 2024 | $61.3 | $71.9 | $55.1 | $16.8 |
Trends in Profitability Over Time
The net loss for the three months ended September 30, 2023, was $12.9 million, indicating a significant increase in net loss year-over-year. For the nine months ended September 30, 2023, the net loss was $39.4 million, reflecting an upward trend in losses as operational costs rise with ongoing research and development activities.
| Period | Net Loss (in millions) |
|---|---|
| Q3 2023 | $12.9 |
| Q3 2024 | $24.5 |
| 9M 2023 | $39.4 |
| 9M 2024 | $61.3 |
Comparison of Profitability Ratios with Industry Averages
As of September 30, 2024, the company's accumulated deficit stood at $201.9 million. The company has yet to generate revenue, which is common in the biotechnology sector during the development phase. Comparatively, the average net profit margin for biotechnology companies is typically low due to high R&D costs, often resulting in net losses during early stages.
Analysis of Operational Efficiency
Research and development expenses surged by 105% from $10.5 million in Q3 2023 to $21.5 million in Q3 2024. This increase reflects the company's commitment to advancing its clinical trials, particularly for its leading product candidate, bexicaserin. The overall operating expenses also increased by 107% year-over-year.
| Expense Type | Q3 2023 (in millions) | Q3 2024 (in millions) | Percentage Change |
|---|---|---|---|
| R&D Expenses | $10.5 | $21.5 | 105% |
| G&A Expenses | $3.1 | $6.7 | 116% |
| Total Operating Expenses | $13.6 | $28.1 | 107% |
Debt vs. Equity: How Longboard Pharmaceuticals, Inc. (LBPH) Finances Its Growth
Debt vs. Equity: How Longboard Pharmaceuticals, Inc. Finances Its Growth
As of September 30, 2024, Longboard Pharmaceuticals, Inc. reported total liabilities of $21.8 million and total stockholders' equity of $275.2 million, resulting in a debt-to-equity ratio of 0.08. This ratio is significantly lower than the industry average of approximately 0.5, indicating a conservative approach to leveraging.
Debt Levels
The company's short-term debt consists of $18.4 million in current liabilities, which include accounts payable and accrued expenses. Long-term debt remains minimal, as the company has primarily relied on equity financing to support its growth.
Debt-to-Equity Ratio Comparison
The debt-to-equity ratio of 0.08 reflects a strong equity base compared to its liabilities. This ratio places Longboard Pharmaceuticals in a favorable light compared to the biotechnology industry, where companies often operate with higher leverage.
Recent Debt Issuances and Credit Ratings
As of the latest reports, Longboard Pharmaceuticals has not engaged in any recent debt issuances. The company maintains a solid financial standing, with no credit ratings indicating significant risk. The focus has been on raising capital through equity offerings.
Equity Financing Activities
In January 2024, the company raised $241.5 million through a follow-on public offering, issuing 11.5 million shares at a price of $21.00 per share. This was a significant increase compared to previous equity raises, which included $23.0 million in February 2023 and $76.2 million from its IPO in March 2021.
Balance Between Debt Financing and Equity Funding
Longboard Pharmaceuticals has strategically balanced its financing through a combination of equity offerings and minimal reliance on debt. The company’s approach to financing allows it to maintain flexibility while minimizing financial risk associated with high leverage.
| Financial Metric | Value |
|---|---|
| Total Liabilities | $21.8 million |
| Total Stockholders' Equity | $275.2 million |
| Debt-to-Equity Ratio | 0.08 |
| Industry Average Debt-to-Equity Ratio | 0.5 |
| Recent Equity Raised (Jan 2024) | $241.5 million |
| Shares Issued (Jan 2024) | 11.5 million |
| Equity Raised (Feb 2023) | $23.0 million |
| IPO Proceeds (Mar 2021) | $76.2 million |
Assessing Longboard Pharmaceuticals, Inc. (LBPH) Liquidity
Assessing Longboard Pharmaceuticals, Inc.'s Liquidity
Current and Quick Ratios
The liquidity position of Longboard Pharmaceuticals, Inc. can be evaluated through its current and quick ratios. As of September 30, 2024, the company had:
- Current Assets: $293.0 million
- Current Liabilities: $18.4 million
The current ratio is calculated as:
Current Ratio = Current Assets / Current Liabilities
Current Ratio = $293.0 million / $18.4 million = 15.93
For the quick ratio, assuming there are no inventories, it remains the same as the current ratio, indicating a strong liquidity position.
Analysis of Working Capital Trends
As of September 30, 2024, Longboard Pharmaceuticals reported:
- Working Capital: $274.7 million
Comparatively, as of December 31, 2023, the working capital was:
- Working Capital: $40.4 million
The significant increase in working capital reflects the company's strong ability to cover its short-term obligations, bolstered by successful capital raises in early 2024.
Cash Flow Statements Overview
Examining the cash flow statements for the nine months ended September 30, 2024, we see:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(54,903) | $(39,840) |
| Net Cash Provided by (Used in) Investing Activities | $(218,559) | $25,794 |
| Net Cash Provided by Financing Activities | $286,985 | $27,181 |
| Net Increase in Cash, Cash Equivalents and Restricted Cash | $13,523 | $13,135 |
In 2024, net cash used in operating activities increased primarily due to a net loss of $61.3 million. However, financing activities provided a substantial inflow, primarily from capital raises.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, Longboard Pharmaceuticals had:
- Cash, Cash Equivalents and Short-Term Investments: $288.4 million
- Accumulated Deficit: $(201.9 million)
The company’s current cash position is strong, and management believes it will be sufficient to fund operations for at least the next 12 months. However, ongoing net losses indicate the need for continued capital raising efforts to support future operational activities.
Is Longboard Pharmaceuticals, Inc. (LBPH) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will examine key financial metrics such as the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, alongside stock price trends and analyst consensus.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a crucial valuation metric that indicates how much investors are willing to pay per dollar of earnings. As of September 30, 2024, the company reported a net loss of $61.3 million for the nine months ended, resulting in a basic net loss per share of $1.63. Given this loss, the P/E ratio cannot be calculated as the earnings are negative.
Price-to-Book (P/B) Ratio
The P/B ratio compares a company's market value to its book value. As of September 30, 2024, the company had total stockholders' equity of $275.2 million, with approximately 39.0 million shares outstanding. If the stock price is $35.26, the market capitalization would be approximately $1.375 billion, resulting in a P/B ratio of approximately 4.99 (calculated as market cap of $1.375 billion divided by book value of $275.2 million).
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is another important metric for understanding valuation. As of September 30, 2024, the company reported total liabilities of $18.4 million and cash equivalents of $288.4 million. The EBITDA for the nine months ended September 30, 2024 was approximately $10.7 million. The enterprise value (EV) can be calculated as follows:
- Market Cap: $1.375 billion
- Cash and Cash Equivalents: $288.4 million
- Total Debt: $18.4 million
- EV = Market Cap + Total Debt - Cash = $1.375 billion + $18.4 million - $288.4 million = $1.105 billion
- EV/EBITDA = EV / EBITDA = $1.105 billion / $10.7 million = 103.63
Stock Price Trends
Over the past 12 months, the stock price has experienced significant fluctuations. The stock price was approximately $6.00 in September 2023 and has risen to approximately $35.26 as of September 30, 2024. This represents an increase of over 487%.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, and its dividend yield is 0.00%. This is typical for companies in the development phase, as they usually reinvest earnings into research and development.
Analyst Consensus on Stock Valuation
Analyst consensus ratings as of the latest reports indicate a mix of "buy" and "hold" recommendations. The average target price set by analysts is approximately $40.00, suggesting potential upside from the current trading levels.
| Metric | Value |
|---|---|
| P/E Ratio | N/A (Net Loss) |
| P/B Ratio | 4.99 |
| EV/EBITDA Ratio | 103.63 |
| Stock Price (12 months ago) | $6.00 |
| Current Stock Price | $35.26 |
| Dividend Yield | 0.00% |
| Analyst Average Target Price | $40.00 |
Key Risks Facing Longboard Pharmaceuticals, Inc. (LBPH)
Key Risks Facing Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc. operates in a high-risk industry characterized by intense competition, regulatory scrutiny, and market volatility. The following outlines the key internal and external risk factors impacting the company's financial health.
Industry Competition
The biopharmaceutical industry is highly competitive, with numerous companies vying for market share. As of September 30, 2024, the company reported an accumulated deficit of $201.9 million, highlighting the financial pressures associated with research and development (R&D) in a crowded market. The competition includes both established players and emerging biotech firms, which may lead to pricing pressures and reduced market access for new products.
Regulatory Changes
Regulatory approvals are critical for the commercialization of new drugs. The company has experienced challenges, including a full clinical hold imposed by the FDA on its proposed studies for product candidate LP659. This hold presents significant delays that could affect the development timeline and associated costs. The company must navigate complex regulatory pathways, which may change and impact its ability to bring products to market.
Market Conditions
Market conditions can significantly affect the company's ability to raise capital. As of September 30, 2024, Longboard reported cash, cash equivalents, and short-term investments of $288.4 million and working capital of $274.7 million. However, adverse macroeconomic conditions, such as inflation and geopolitical tensions, could lead to diminished investor confidence and reduced liquidity in the financial markets, making it challenging to secure funding for ongoing operations.
Operational Risks
Operational risks are inherent in the company's business model, particularly related to clinical trials and R&D activities. The company reported net losses of $61.3 million for the nine months ended September 30, 2024, reflecting the high costs associated with these activities. Any delays or failures in clinical trials can lead to increased costs and a depletion of financial resources.
Financial Risks
The company has incurred substantial operating losses since its inception, with net losses of $24.5 million for the three months ended September 30, 2024. The need for continuous funding through public or private equity offerings is critical, as the company does not expect to generate revenue from product sales until successful completion of clinical trials and regulatory approval. This financial instability may hinder growth and operational capacity.
Strategic Risks
Strategic risks include the company’s dependence on a limited number of product candidates. The success of its primary product, bexicaserin (LP352), is paramount to the company’s future. Any setbacks in its development could adversely affect Longboard's market position and financial health. The company is also engaged in a merger agreement, which introduces additional uncertainties and potential operational disruptions.
Mitigation Strategies
In response to these risks, the company has implemented several mitigation strategies. As of September 30, 2024, management believes that existing cash reserves will support operations for at least the next 12 months. The company also plans to continue exploring various funding avenues, including collaborations and partnerships, to enhance its capital position.
| Risk Category | Description | Current Financial Impact |
|---|---|---|
| Industry Competition | High competition affecting pricing and market access | Accumulated deficit of $201.9 million |
| Regulatory Changes | FDA clinical holds and changing regulations | Delays in product candidate development |
| Market Conditions | Volatility affecting capital raising ability | Cash and equivalents of $288.4 million |
| Operational Risks | High costs associated with clinical trials | Net losses of $61.3 million for nine months ended September 30, 2024 |
| Financial Risks | Continuous need for funding | Net loss of $24.5 million for three months ended September 30, 2024 |
| Strategic Risks | Dependence on limited product candidates | Potential impact from merger agreement uncertainties |
Future Growth Prospects for Longboard Pharmaceuticals, Inc. (LBPH)
Future Growth Prospects for Longboard Pharmaceuticals, Inc.
Analysis of Key Growth Drivers
Longboard Pharmaceuticals is poised for growth driven by multiple factors:
- Product Innovations: The company is advancing its lead investigational product, bexicaserin, which is currently in Phase 2 clinical trials for the treatment of various psychiatric disorders.
- Market Expansions: With a robust pipeline, including LP659, which targets multiple sclerosis, the company aims to capture additional market share in the neurology sector.
- Acquisitions: The recent merger agreement with Lundbeck A/S, announced on October 14, 2024, may enhance its capabilities and market reach significantly.
Future Revenue Growth Projections and Earnings Estimates
Projected revenue growth is contingent on successful clinical trials and subsequent product launches:
- Revenue from product sales is not expected until regulatory approvals are obtained, which may take several years.
- Analysts forecast a potential market value exceeding $1 billion for bexicaserin upon approval, considering the unmet medical needs in its target indications.
- For the nine months ended September 30, 2024, the net loss was $61.3 million, indicating significant investment in R&D which is expected to yield long-term revenue growth.
Strategic Initiatives or Partnerships That May Drive Future Growth
Key strategic initiatives include:
- Partnership with Lundbeck A/S to leverage their extensive market presence and expertise in commercialization.
- Investment in clinical trials, with research and development expenses reaching $55.1 million for the nine months ended September 30, 2024, a 75% increase from the previous year.
Competitive Advantages That Position the Company for Growth
The company benefits from several competitive advantages:
- Strong Financial Position: As of September 30, 2024, Longboard had cash, cash equivalents, and short-term investments of $288.4 million, providing a solid foundation for ongoing operations.
- Robust Pipeline: A diverse pipeline of product candidates, including ongoing clinical trials, positions the company favorably against competitors.
- Experienced Management Team: Leadership with a strong track record in drug development and commercialization enhances strategic decision-making.
| Financial Metrics | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Research and Development Expenses | $55.1 million | $31.6 million |
| General and Administrative Expenses | $16.8 million | $9.6 million |
| Net Loss | $61.3 million | $39.4 million |
| Cash, Cash Equivalents, and Short-term Investments | $288.4 million | $48.5 million |
Longboard Pharmaceuticals, Inc. (LBPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Longboard Pharmaceuticals, Inc. (LBPH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Longboard Pharmaceuticals, Inc. (LBPH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Longboard Pharmaceuticals, Inc. (LBPH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.